ArticleDrugs - real world outcomes2020

Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes.

Mark RedellPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.